SEARCH

SEARCH BY CITATION

References

  • 1
    Everhart J, Wei Y, Eng H, Charlton M, Persing D, Wiesner R, et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 1999; 29:12201226.
  • 2
    Prieto M, Berenguer M, Rayon J, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology 1999; 29:250256.
  • 3
    Gane E, Portmann B, Naoumov N, Smith H, Underhill J, Donaldson P, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334:815820.
  • 4
    Feray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999; 117:619625.
  • 5
    Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32:852858.
  • 6
    Farci P, Shimoda A, Wong D, Cabezon T, DeGioannis D, Strazzera A, et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A 1996; 93:1539415399.
  • 7
    Krawczynski K, Alter M, Tankersley D, Beach M, Robertson B, Lambert S, et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 1996; 173:822828.
  • 8
    Feray C, Gigou M, Samuel D, Ducot B, Maisonneuve P, Reynes M, et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med 1998; 128:810816.
  • 9
    Willems B, Ede M, Marotta P, Grieg PD, Lilly L, Kneteman N, et al. Anti-HCV immunoglobulins for the prevention of graft infection in HCV-related liver transplantation [abstract]. J Hepatol 2002; 36:S96A.
  • 10
    Ilan E, Arazi J, Nussbaum O, Zauberman A, Eren R, Lubin I, et al. The hepatitis C virus (HCV)-Trimera mouse: A model for evaluation of agents against HCV. J Infect Dis 2002; 185:153161.
  • 11
    McCaughan GW, Zekry A. Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl 2002; 8(suppl 1):S7S13.
  • 12
    Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35:680687.
  • 13
    Gane E, Naoumov N, Qian K, Mondelli M, Maertens G, Portmann B, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110:167177.
  • 14
    Gretch D, Bacchi C, Corey L, de la Rosa C, Lesniewski R, Kowdley K, et al. Persistent hepatitis C virus infection after liver transplantation: Clinical and virological features. Hepatology 1995; 22:19.
  • 15
    Fukumoto T, Berg T, Ku Y, Bechstein W, Knoop M, Lemmens H, et al. Viral dynamics of hepatitis C early after orthotopic liver transplantation: Evidence for rapid turnover of serum virions. Hepatology 1996; 24:13511354.
  • 16
    Ballardini G, De Raffele E, Groff P, Biovlac-Sage P, Grassi A, Ghetti S, et al. Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. Liver Transpl 2002; 8:1020.
  • 17
    Terrault N, Friesenhahn M, Anderson F, Pawlotsky J, Perrillo R, Gordon S, et al. Decline in HCV viral load in chronically-infected subjects during the first eight weeks of therapy with standard interferon/ribavirin is highly predictive of virological outcome [abstract]. Hepatology 2002; 36:294A.
  • 18
    Poynard T, Regimbeau C, Myers R, Thevenot T, Leroy V, Mathurin P, et al. Interferon for acute hepatitis C. Cochrane Database Syst Rev 2002 2002; 1:CD000369.
  • 19
    Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345:14521457.
  • 20
    Sheiner P, Boros P, Klion F, Thung S, Schluger L, Lau J, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28:831838.
  • 21
    Singh N, Gayowski T, Wannstedt CF, Shakil AO, Wagener MM, Fung JJ, et al. Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: A prospective, randomized, controlled trial. Transplantation 1998; 65:8286.
  • 22
    Manzarbeitia C, Tepermann L, Chalasani N, Sheiner P, Wiesner R, Marks I, et al. 40 kDa peginterferon as prophylaxis against HCV recurrence after liver transplantation: Preliminary results of a randomised, multicenter trial [abstract]. Hepatology 2001; 34:406A.
  • 23
    Mazzaferro V, Tagger A, Schiavo M, Regalia E, Pulvirenti A, Ribero ML, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 2001; 33:13551357.
  • 24
    Terrault N, Khalili M, Bollinger K, Roberts J, Ascher N. Limitations in the use of a prophylactic antiviral strategy in hepatitis C infected patients undergoing liver transplantation. Hepatology 2002; 36:177A.
  • 25
    Jain A, Eghtesad B, Venkataramanan R, Fontes P, Kashyap R, Dvorchik I, et al. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection. Liver Transpl 2002; 8:10071013.
  • 26
    Mazzaferro V, Regalia E, Pulvirenti A, Tagger A, Andreola S, Pasquali M, et al. Prophylaxis against HCV recurrence after liver transplantation: Effect of interferon and ribavirin combination. Transplant Proc 1997; 29:519521.